INMB · Inmune Bio, Inc. · Webcasts, Transcripts & Audio
$0.89
0.00 (-0.47%)
At close · Nov 20
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Going-concern doubt
— flagged Nov 5, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions and events raise substantial doubt about the Company’s ability to continue as a going concern. As a result, the Company has concluded that management’s plans do not alleviate substantial doubt about the Company’s ability to continue as a going concern.”View the 10-Q filed Nov 5, 2026
Market Cap
$27.68M
Shares
30.96M
Volume · Nov 20
7246
Avg daily vol (3M)
342.92K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Inmune Bio, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Inmune Bio, Inc. (INMB), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Earnings call
FY26 · Q3
2026-11-05
Inmune Bio, Inc. (INMB) Q3 2026 Earnings Call Transcript
Confident tone
Clinical need in RDEB
Capital allocation
Commercial manufacturing readiness
Diluted EPS
$-0.17
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-03-31
Date not confirmed
Inmune Bio, Inc. (INMB) Q1 2026 Earnings Call Transcript
Positive tone
CORDStrom regulatory filings and MAA submission
RDEB program and branding
XPro program and MINDFuL study
Diluted EPS
$-0.20
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2025-12-31
Date not confirmed
Inmune Bio, Inc. (INMB) Q4 2025 Earnings Call Transcript
Positive tone
CORDStrom RDEB regulatory progress
XPro Alzheimer's program
INKmune prostate cancer program
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-10-30
Inmune Bio, Inc. (INMB) Q3 2025 Earnings Call Transcript
Confident tone
CORDStrom RDEB regulatory progress
Itch reduction / systemic benefit in RDEB
INKmune prostate cancer Phase II
Diluted EPS
$-0.24
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Inmune Bio, Inc. (INMB) Q2 2025 Earnings Call Transcript
Positive tone
XPro Phase II MINDFuL trial in Alzheimer's
CORDStrom for RDEB regulatory submissions
Strategic partnership exploration
Diluted EPS
$-1.05
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Inmune Bio, Inc. (INMB) Q1 2025 Earnings Call Transcript
Confident tone
CORDstrom / RDEB program
XPro market opportunity
INKmune prostate cancer program
Revenue
$50,000
▲ 257.1% YoY Diluted EPS
$-0.43
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-27
Inmune Bio, Inc. (INMB) Q4 2024 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-01
Inmune Bio, Inc. (INMB) Q3 2024 Earnings Call Transcript
Confident tone
XPro ADO2 Phase II Alzheimer’s trial enrollment complete
Ease of delivery / outpatient administration
Treatment-resistant depression Phase II program
Diluted EPS
$-0.60
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-02
Inmune Bio, Inc. (INMB) Q2 2024 Earnings Call Transcript
Confident tone
INKmune NK cell oncology program
XPro Phase II Alzheimer's trial (AD02)
Treatment-resistant depression program
Diluted EPS
$-0.50
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-13
Inmune Bio, Inc. (INMB) Q1 2024 Earnings Call Transcript
Positive tone
Alzheimer's Phase II AD02 trial enrollment and design
XPro long-term safety and patient experience
INKmune NK cell oncology platform (renal cell carcinoma)
Revenue
$14,000
▼ 63.2% YoY Diluted EPS
$-0.61
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-29
Inmune Bio, Inc. (INMB) Q4 2023 Earnings Call Transcript
Confident tone
XPro Phase 2 Alzheimer's trial design and confidence
INKmune prostate cancer trial
Pipeline expansion beyond Alzheimer's
Revenue
$28,000*
▼ 71.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-01
Inmune Bio, Inc. (INMB) Q3 2023 Earnings Call Transcript
Revenue
$43,000
▼ 56.1% YoY Diluted EPS
$-0.48
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Inmune Bio, Inc. (INMB) Q2 2023 Earnings Call Transcript
Revenue
$46,000
▲ 187.5% YoY Diluted EPS
$-0.36
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
Inmune Bio, Inc. (INMB) Q1 2023 Earnings Call Transcript
Revenue
$38,000
▼ 76.7% YoY Diluted EPS
$-0.36
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-03
Inmune Bio, Inc. (INMB) Q4 2022 Earnings Call Transcript
Revenue
$97,000*
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-02
Inmune Bio, Inc. (INMB) Q3 2022 Earnings Call Transcript
Revenue
$98,000
▲ 600% YoY Diluted EPS
$-0.43
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Inmune Bio, Inc. (INMB) Q2 2022 Earnings Call Transcript
Revenue
$16,000
Diluted EPS
$-0.38
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-06
Inmune Bio, Inc. (INMB) Q1 2022 Earnings Call Transcript
Revenue
$163,000
▲ 3975% YoY Diluted EPS
$-0.39
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-04
Inmune Bio, Inc. (INMB) Q4 2021 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-04
Inmune Bio, Inc. (INMB) Q3 2021 Earnings Call Transcript
Revenue
$14,000
Diluted EPS
$-0.55
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
Inmune Bio, Inc. (INMB) Q2 2021 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Inmune Bio, Inc. (INMB) Q1 2021 Earnings Call Transcript
Revenue
$4,000
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-03-05
Inmune Bio, Inc. (INMB) Q4 2020 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-06
Inmune Bio, Inc. (INMB) Q3 2020 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Inmune Bio, Inc. (INMB) Q2 2020 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-15
Inmune Bio, Inc. (INMB) Q1 2020 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-03-12
Inmune Bio, Inc. (INMB) Q4 2019 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Showing 1–27 of 27 webcasts
Key facts
CIK
1711754
CUSIP
45782T105
13F (30d)
70 filings
58 filers
Visit website
Investor relations